



BIRD virtual program

WEDNESDAY 9TH FEBRUARY

Session 1:

CHAIRS: M. FERRANTE (UZ Leuven), M. TRUYENS (UZ Gent)

09:00 **Invited lecture:** Sphingosine 1-phosphate modulation and mechanisms to target immune cell trafficking in IBD.

Dr Bram Verstockt / UZ Leuven

09:25 **I 01** Endoscopic outcome in tofacitinib treated patients correlated with tofacitinib tissue exposure.
B. VERSTOCKT (1), D. ALSOUD (2), J. VAN OOSTROM (3), J. SMITH (4), J. STYLLI (4), S. SINGH (4), S. VAN GENNEP (3), P. RAHIMIAN (4), J. SABINO (1), M. FERRANTE (1), S. SINGH (4), G. D'HAENS (3), S. VERMEIRE (1) / [1] UZLeuven, [2] KULeuven, [3] Amsterdam UMC, The Netherlands, [4] Progenity, San Diego, USA

09:35 **I 02** Remission state in inflammatory bowel disease patients on anti TNF or vedolizumab: aconfocal endomicroscopy study.
J. LOLY, S. VIEUJEAN, C. REENAERS, C. VAN KEMSEKE, L. SEIDEL, J. SOMJA, E. LOUIS / CHU Liege

09:45 **I 03** Biological therapies and small molecules are efficacious in patients with moderate-to-severeulcerative proctitis.
P. LEMMENS, J. SABINO, E. DUBOIS, B. VERSTOCKT, S. VERMEIRE, M. FERRANTE / UZ Leuven

09:55 **I 04** The dynamic of the molecular classification of Crohn's disease.
N. SEYED TABIB (1), S. VERSTOCKT (1), B. VERSTOCKT (2), SABINO (2), M. FERRANTE (2), S. VERMEIRE (2) / [1] KULeuven, [2] UZ Leuven

10:05 **I 05** Matrix Gla protein, a potential marker of tissue remodelling and physiological ageing of the gut in Crohn's Disease.
S. VIEUJEAN (1), P. DELANAYE (1), L. SEIDEL (1), E. CAVALIER (1), N. PIERRE (2), E. LOUIS (1) / [1] CHU Liège, [2] U Liège

10:15-10:45 **Satellite Symposium: Coffee Break Session: VIATRIS**
Post-operative management after ileocecal resection in CD patients
Speaker: Triana Lobaton / UZ Gent

10:15-11:00 **Coffee break**

Session 2:

CHAIRS: J. GELDOF (UZ Gent), C. LIEFFERINCKX (ULB)

11:00 **I 06** A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent inflammatory bowel disease and fatigue (Trp-IBD).
M. TRUYENS (1), T. LOBATON ORTEGA (1), A. PEETERS (1), M. FERRANTE (2), S. VERMEIRE (2), P. BOSSUYT (3), L. POUILLON (3), P. DEWINT (4), A. CREMER (5), H. PEETERS (6), G. LAMBRECHT (7), E. LOUIS (8), J. RAHIER (9), O. DEWIT (10), V. MULS (11), T. HOLVOET (12), L. VANDERMEULEN (13), G. GONZALES (14), D. LAUKENS (1), M. DE VOS (1) / [1] UZ Gent, [2] UZ Leuven, [3] Imelda Hospital, Bonheiden, [4] Maria Middelaars Ziekenhuis, Gent, [5] ULB Erasme, Brussels, [6] AZ Sint-Lucas, Gent, [7] AZ Damiaan, Oostende, [8] CHU Liège, [9] CHU UCL Namur, Yvoir, [10] UCL Saint Luc, Brussels, [11] ULB Saint-Pierre, Brussels, [12] AZ Nikolaas, [13] UZ Brussel, [14] Wageningen University and Research, The Netherlands

11:10 **I 07** Distinct molecular profiles between idiopathic cryptoglandular and Crohn-related perianal fistulas.
B. VERSTOCKT, S. VERSTOCKT, G. BISLENGHI, J. SABINO, M. FERRANTE, A. D'HOORE, S. VERMEIRE / UZ Leuven

11:20 **I 08** Efficacy and safety of bone marrow-derived mesenchymal stem cells in refractory perianalfistulae in Crohn's disease: results from a prospective monocentric study.
C. REENAERS, S. VIEUJEAN, C. COIMBRA, R. GILLARD, P. MEUNIER, L. BOUTAFFALA, E. LOUIS / CHU Sart Tilman, Liège

11:30 **Invited lecture:** Lipids in inflammatory bowel disease, an opportunity to control the inflammation?
Giulio Muccioli / Louvain Drug Research Institute, UCL

12:00 **Symposium Lunchtime Session: GALAPAGOS**
Evolutions in IBD: towards holistically approaching remission
Speakers : Charlie Lees / Edinburgh, UK and Bram Verstockt, UZ Leuven,

12:45-13:30 **Lunch break**

SESSION 3:

CHAIRS: O. DEWIT (UCL), T. LOBATON (UZ Gent)

- 13:30 **INVITED LECTURE:** How to treat a severe colitis in 2022? New drugs, new algorithm?
David Laharie / CHU Bordeaux
- 13:55 **I 09** Changes in colectomy for ulcerative colitis during the last two decades: an in-depth retrospective analysis.
G. LE COSQUER (1), L. CAPIRCHIO (2), P. RIVIÈRE (1), N. DE SURAY (2), F. PoulleNOT (1), B. DE VROEY (2), A. BERGER (1), M. DENIS (2), F. ZERBIB (1), R. BACHMANN (2), C. REMUE (2), B. CELERIER (1), D. LEONARD (2), Q. DENOST (1), A. KARTHEUSER (2), D. LAHARIE (1), O. DEWIT (2) / [1] CHU Bordeaux, Hôpital Haut Levêque, Pessac, France, [2] UCL Saint-Luc, Brussels
- 14:05 **I 10** Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian openlabel multicentre pilot study.
A. OUTTIER (1), E. LOUIS (2), O. DEWIT (3), G. SCHOPS (1), B. VERSTOCKT (1), J. SABINO (1), S. VERMEIRE (1), M. FERRANTE (1) / [1] UZ Leuven [2] CHU Sart-Tilman, Liège, [3] UCL Saint-Luc, Brussels
- 14:15 **I 11** Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn's disease: a Belgian multi-centric cohort study.
D. ALSOUD (1), D. FRANCHIMONT (2), F. D'HEYGERE (3), P. BOSSUYT (4), A. VIJVERMAN (5), P. VAN HOOTEGEM (6), J. SABINO (7), A. CREMER (2), S. VERMEIRE (7), M. FERRANTE (7) / [1] KU Leuven, [2] ULB Erasme, Brussels, [3] AZ Groeninge, Kortrijk, [4] Imelda Hospital, Bonheiden, [5] CHR Citadelle, Liège, [6] AZ Sint-Lucas Brugge, Assebroek/ Brugge, [7] UZ Leuven
- 14:25 **I 12** Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis.
D. ALSOUD (1), G. COMPERNOLLE (1), S. TOPS (1), J. SABINO (2), M. FERRANTE (2), D. THOMAS (1), G. DE HERTOOGH (2), S. VERMEIRE (2), B. VERSTOCKT (2) / [1] KU Leuven, [2] UZ Leuven
- 14:35 **I 13** Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn's disease.
D. ALSOUD (1), J. SABINO (2), M. FERRANTE (2), S. VERMEIRE (2), B. VERSTOCKT (2) / [1] KU Leuven, [2] UZ Leuven
- 14:45 **I 14** Prevalence and outcomes of Sars-cov2 infection in patients with Immune-Mediated Inflammatory Diseases (IMID): a monocentric Belgian population-based retrospective study.
C. VUCKOVIC (1), A. HOYOIS (2), J. MUNGWETE (2), L. DE BELLEFON (2), C. MUSALA (2), J. MASSART (2), S. DI ROMANA (2), V. MULS (2) / [1] ULB Erasme, Bruxelles, [2] ULB Saint-Pierre

14:55 **Satellite Symposium AbbVie**
Pathogenesis of ulcerative colitis and role of the JAK-STAT pathway.
Sebastian Zeissig / Dresden, Germany

14:55-15:40 **Coffee break**

SESSION 4:

CHAIRS: C. REENAERS (ULG), J. SABINO (UZ Leuven)

15:40 **I 15** Evaluating segmental healing with the modified Mayo endoscopic score (MMES) has a clear additional value in predicting long-term outcome in patients with ulcerative colitis: results from a prospective cohort study.
M. LENFANT (1), B. VERSTOCKT (2), J. SABINO (2), S. VERMEIRE (2),
M. FERRANTE (2) / [1] KU Leuven, [2] UZ Leuven

15:50 **I 16** Prophylactic versus endoscopy-driven treatment of Crohn's postoperative recurrence: A retrospective, multicentric European study.
J. GELDOF (1), M. TRUYENS (1), M. HANSSENS (1), T. HOLVOET (2),
A. ELORZA (3), V. BOUILLON (4), V. MARTINS (5), K. ARGYRIOU (6),
M. DICULESCU (7), A. MOENS (8), E. THEODORAKI (9), J. PEDRO (10),
P. NIKOLAOU (11), F. BAERT (12), R. FERREIRO-IGLESIAS (13), H. PEETERS (14),
M. CASANOVA (15), P. EDER (16), R. PORTER (17), T. KARAKAN (18),
F. MESONERO (19), J. REVÉS (20), E. VAN DYCK (21),
A. JAUREGUI-AMEZAGA (22), M. MAÑOSA (23), P. RIVIÈRE (24),
L. MOSQUERA (25), F. PORTELA (26), T. LOBATON (1) / [1] UZ Gent, [2] AZ
Nikolaas, Sint-Niklaas, [3] Hospital Universitario de Galdako, Spain,
[4] ULB Erasme, Brussels, [5] Algarve University Hospital Center,
Faro, Portugal, [6] University Hospital of Larisa, Greece, [7] Carol Davila
University of Medicine Bucharest, Romania, [8] Imelda Hospital, Bonheiden,
[9] University Hospital Heraklion, Greece, [10] Hospital Santa Maria, Lisbon,
Portugal, [11] Venizeleio General Hospital, Heraklion, Greece, [12] AZ Delta,
Roeselare, [13] Hospital Clinico Universitario de Santiago, Santiago de
Compostela, Spain, [14] AZ Sint-Lucas, Ghent, [15] Hospital Universitario de La
Princesa, Madrid, Spain, [16] Poznan University of Medical Sciences, Poznan,
Poland, [17] Western General Hospital, NHS Lothian, Edinburgh, [18] Gazi
University, Ankara, Turkey, [19] Hospital Universitario Ramon y Cajal, Madrid,
Spain, [20] Hospital Beatriz Angelo, Lisbon, Portugal, [21] AZ Klina, Brasschaat,
[22] UZ Antwerpen, [23] Hospital Universitario Germans Trias i Pujol,
Barcelona, Spain, [24] CHU Bordeaux, Hôpital Haut Levêque, Pessac, France,
[25] Hospital del Mar, Barcelona, Spain, [26] Hospital and University of
Coimbra, Portugal

- 16:00 **I 17** Vaccination coverage significantly increased after implementation of a vaccination tool in the electronic patient health record.
L. FIERENS (1), E. DE DYCKER (2), J. JOLY (2), T. VANHOUTVIN (2),
P. VERSCHUEREN (2), P. DE HAES (2), P. DE MUNTER (2), J. SABINO (2),
S. VERMEIRE (2), M. FERRANTE (2) / [1] KU Leuven, [2] UZ Leuven
- 16:10- **I 18** Type of patient education impacts the willingness to switch from an IV to SC of a biological inpatients with IBD: a multicentre, comparative study.
K. ASNONG (1), E. DE DYCKER (2), E. HOEFKENS (1), P. GEENS (2),
N. LEMBRECHTS (1), T. LAMBRECHTS (2), I. VAN DE SCHOOT (1), A. PAPS (2),
L. POUILLON (1), S. VERMEIRE (2), P. BOSSUYT (1), M. FERRANTE (2) /
[1] Imelda Hospital, Bonheiden, [2] UZ Leuven
- 16:20 **I 19** Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls.
K. ARNAUTS, P. SUDHAKAR, S. VERSTOCKT, C. LAPIERRE, S. POTCHE,
C. CAENEPEEL, B. VERSTOCKT, J. RAES, S. VERMEIRE, J. SABINO, C. VERFAILLIE,
M. FERRANTE / KU Leuven
- 16:30 **I 20** Standardized fecal microbiota transplantation including microbial based donor selection in active Ulcerative Colitis patients: A randomized, placebo controlled clinical trial.
C. CAENEPEEL (1), S. DELEU (1), K. ARNAUTS (1), J. VAZQUEZ CASTELLANOS (2),
S. BRAEKELEIRE (1), K. MACHIELS (1), F. BAERT (3), F. MANA (4),
L. POUILLON (5), P. HINDRYCKX (6), T. LOBATON (6), E. LOUIS (7),
D. FRANCHIMONT (8), M. FERRANTE (1), J. SABINO (1), S. VIEIRA-SILVA (2),
G. FALONY (2), J. RAES (2), S. VERMEIRE (9) / [1] KU Leuven, [2] Rega
institute, Leuven, [3] AZ Delta, Roeselare, [4] UZ Brussel, Jette, [5] Imelda
Hospital, Bonheiden, [6] UZ Gent, [7] CHU of Liège, [8] ULB Erasme, Brussels,
[9] UZ Leuven
- 16:40- **Invited lecture** : Fecal transplantation in IBD, is there any hope in a near future?
Harry Sokol / Saint-Antoine Paris, France
- 17:05 **Coffee Break**
- 17:30 **BIRD general assembly**
-

e-Posters:

- I 21 High acetate concentration reduces inflammation in organoid-derived epithelial monolayer from patients with Ulcerative Colitis.
S. DELEU (1), K. ARNAUTS (1), K. MACHIELS (1), G. HUYS (1), J. THEVELEIN (2), J. RAES (1), S. VERMEIRE (1) / [1] KULeuven, [2] Erasmus High School, Brussels
- I 22 Predictive models for assessing the response to ustekinumab in Crohn's disease patients.
A. HUBERT (1), J. TOUBEAU (1), J. BOTTIEAU (1), D. FRANCHIMONT (2), F. VALLÉE (1), C. LIEFFERINCKX (2) / [1] University of Mons, [2] ULB Erasme, Brussels,
- I 23 Experience of using the autoimmune nutrition protocol in patients with autoimmune diseases of the digestive tract.
T. HAURYLENKA / Republican Research Center for Radiation Medicine and Human Ecology, Gomel, Belarus
- I 24 Infliximab re-challenge: could it be an option in refractory IBD patients?
M. TRUYENS (1), E. PIJOAN COMAS (2), E. GLORIEUS (1), J. GELDOF (1), T. LOBATON ORTEGA (1) / [1] UZ Gent, [2] Palamós Hospital, Spain
- I 25 Safety analysis of filgotinib for ulcerative colitis: results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension Study.
S. VERMEIRE (1), M. FERRANTE (1), S. SCHREIBER (2), M. WATANABE (3), C. YUN (4), Y. ZHOU (4), S. ZHAO (4), J. HSIEH (4), U. MOERCH (4), G. ROGLER (5), E. LOFTUS JR (8) / [1] UZ Leuven, [2] University Hospital Schleswig-Holstein, Germany, [3] Tokyo Medical and Dental University, Japan, [4] Gilead Sciences, Inc., California, USA, [5] University Hospital of Zurich, Switzerland, [8] Mayo Clinic College of Medicine, Minnesota, USA
- I 26 Corticosteroid-free remission of Ulcerative Colitis with filgotinib maintenance therapy: post hoc analysis of the phase 2b/3 SELECTION study.
S. VERMEIRE (1), M. FERRANTE (1), E. LOFTUS JR (2), B. FEAGAN (3), C. YUN (4), J. HSIEH (4), X. LIU (4), S. ZHAO (4), U. MOERCH (4), W. SANDBORN (7), T. HIBI (8) / [1] UZ Leuven, [2] Mayo Clinic College of Medicine, Minnesota, USA, [3] Western University, ON, Canada, [4] Gilead Sciences, Inc., California, USA, [5] University of California San Diego, La Jolla, USA, [8] Kitasato Institute Hospital, Japan
- I 27 Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: post hoc analysis of the phase 2b/3 SELECTION study.
M. FERRANTE (1), S. VERMEIRE (1), S. DANESE (2), T. HIBI (3), T. RITTER (4), J. DINOSO (5), J. HSIEH (5), C. YUN (5), J. ZHANG (5), S. ZHAO (5), E. LOFTUS JR (8), G. ROGLER (9) / [1] UZ Leuven, [2] Humanitas Clinical and Research Center, Italy,

[3] Kitasato Institute Hospital, Japan, [4] GI Alliance, Texas, USA, [5] Gilead Sciences, Inc., California, USA, [8] Mayo Clinic College of Medicine, Minnesota, USA, [9] University Hospital of Zurich, Switzerland

- I 28 Early achievement of partial Mayo score remission and IBDQ normalization in patients with ulcerative colitis treated with filgotinib in the phase 2b/3 SELECTION study.
M. FERRANTE (1), S. VERMEIRE (1), A. OORTWIJN (2), B. FEAGAN (3), C. YUN (4), J. ZHANG (4), L. PEYRIN-BIROULET (5), S. DANESE (6) / [1] UZ Leuven, [2] Galapagos BV, The Netherlands, [3] Western University, ON, Canada, [4] Gilead Sciences, Inc., California, USA, [5] Nancy University Hospital, France, [6] Humanitas Research Hospital, Italy
- I 29 The clinical decision support tool has low performance in predicting outcome to ustekinumab in Crohn's disease.
D. ALSOUD (1), J. SABINO (2), M. FERRANTE (2), B. VERSTOCKT (2), S. VERMEIRE (2) / [1] KULeuven, [2] UZ Leuven
- I 30 Associations of blood derived immune cell transcriptional signatures with disease location in IBD.
P. SUDHAKAR (1), B. VERSTOCKT (2), J. CREMER (1), S. VERSTOCKT (1), J. SABINO (2), M. FERRANTE (2), S. VERMEIRE (2) / [1] KULeuven, [2] UZ Leuven
- I 31 Surveying the use of Complementary Alternative Medicines among IBD Patients.
P. SUDHAKAR (1), R. STIERS (2), E. DE DYCKER (2), P. GEENS (2), A. PAPS (2), T. LAMBRECHTS (2), B. KEERSMAEKERS (2), J. SABINO (2), M. FERRANTE (2), S. VERMEIRE (2), B. VERSTOCKT (2) / [1] KULeuven, [2] UZ Leuven
- I 32 Subcutaneous infliximab CT-P13 in clinical practice: A Belgian single center experience.
L. CORNELIS, E. DE JONCKERE, J. BOSSUYT, H. VANPOUCKE, L. DESOMER, D. DE WULF, F. BAERT / AZ Delta, Roeselare